Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer: a Proof of Concept Study (H3RAKLES)

NCT07193394 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT07193394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07193394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer: a Proof of Concept Study (H3RAKLES)
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Recruiting
Start date
January 31, 2026
Completion date
June 8, 2029
Enrollment
20 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer ( her2 negative), unresectable breast cancer